awmsg logo



glecaprevir/pibrentasvir (Maviret®)


Reference No. 3007

Publication date:
19/10/2017


Appraisal information

glecaprevir/pibrentasvir (Maviret®) 100 mg/40 mg film-coated tablet


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1917
Ratification by Welsh Government: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID1085) NICE GUIDANCE ISSUED DECEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download